AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listing, of claims in the application:

1. (Original) A microemulsion preconcentrate comprising:

an active component;

an oil;

a surfactant; and

a hydrophilic solvent selected from the group consisting of propylene glycol diacetate, propylene glycol monoacetate, and salts of the forgoing materials.

2. (Original) The microemulsion preconcentrate of claim 1, wherein the ratio by weight of the sum of oil, hydrophilic solvent, and surfactant to the active component is 0.5-10.

3. (Original) The microemulsion preconcentrate of claim 1, wherein the ratio by weight of oil, hydrophilic solvent, and surfactant is 0.5-60: 0.5-60:0.5-80.

4. (Currently Amended) The microemulsion preconcentrate of claim 1, wherein the active component is selected from the group consisting of piroxicam, ketorolac, ketopropen, acetaminophen, aceclofenac, naproxen, gabapentin, amlodipine, felodipine, enalapril, isosorbide dinitrate, terazocine, carvedilol, nifedipine, captopril, itraconazole, fluconazole, ketoconazole, fluorouracil, paclitaxel, adriamycin, estradiol, progestin, testosterone, alprostadil, donepezil, rivastigmine, physostigmine, adrenol™, alendronate, cyclosporin, tacrolimus, ondansetron, scopolamine, meclizine, fluoxetine, venlafaxine, and pharmaceutically acceptable salts of the forgoing components.

5. (Original) The microemulsion preconcentrate of claim 1, wherein the active component is cyclosporin.

6. (Currently Amended) An oral pharmaceutical preparation comprising: ~~the~~a microemulsion preconcentrate including:~~according to any one of claims 1 through 5~~

an active component;

an oil;

a surfactant; and

a hydrophilic solvent selected from the group consisting of propylene glycol diacetate, propylene glycol monoacetate, and salts of the forgoing materials.

7. (Currently Amended) ~~An~~The oral pharmaceutical preparation ~~according to~~of claim 6, wherein the oral pharmaceutical preparation is soft capsule, gelatin-sealed hard capsule, or liquid.

8. (New) The oral pharmaceutical preparation of claim 6, wherein the ratio by weight of the sum of oil, hydrophilic solvent, and surfactant to the active component is 0.5-10.

9. (New) The oral pharmaceutical preparation of claim 6, wherein the ratio by weight of oil, hydrophilic solvent, and surfactant is 0.5-60: 0.5-60:0.5-80.

10. (New) The oral pharmaceutical preparation of claim 6, wherein the active component is selected from the group consisting of piroxicam, ketorolac, ketopropen, acetaminophen, aceclofenac, naproxen, gabapentin, amlodipine, felodipine, enalapril, isosorbide dinitrate, terazocine, carvedilol, nifedipine, captopril, itraconazole, fluconazole, ketoconazole, fluorouracil, paclitaxel, adriamycin, estradiol, progestin, testosterone, alprostadil, donepezil, rivastigmine, physostigmine, adrenol™, alendronate, cyclosporin, tacrolimus, ondansetron, scopolamine, meclizine, fluoxetine, venlafaxine, and pharmaceutically acceptable salts of the forgoing components.

11. (New) The oral pharmaceutical preparation of claim 1, wherein the active component is cyclosporin.